{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:04:43Z","timestamp":1788887083951,"version":"build-2803163510"},"reference-count":62,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:p>Patients with B\u2010cell hematologic malignancies who progress through first\u2010 or second\u2010line chemotherapy have a poor prognosis. Early clinical trials with autologous anti\u2010<jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>19 chimeric antigen receptor (<jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content>) T cells have demonstrated promising results for patients who have relapsed or refractory disease. Lymphodepleting conditioning regimens, including cyclophosphamide, fludarabine, pentostatin, bendamustine, interleukin\u20102, and total body irradiation, are often administered before the infusion of <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T cells, allowing for greater T\u2010cell expansion. The major toxicity associated with <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T\u2010cell infusions is cytokine release syndrome (<jats:styled-content style=\"fixed-case\">CRS<\/jats:styled-content>), a potentially life\u2010threatening systemic inflammatory disorder. The quick onset and progression of <jats:styled-content style=\"fixed-case\">CRS<\/jats:styled-content> require rapid detection and intervention to reduce treatment\u2010related mortality. Management with tocilizumab can help ameliorate the symptoms of severe <jats:styled-content style=\"fixed-case\">CRS<\/jats:styled-content>, allowing steroids, which diminish the expansion and persistence of <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T cells, to be reserved for tocilizumab\u2010refractory patients. Other toxicities of <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T\u2010cell therapy include neutropenia and\/or febrile neutropenia, infection, tumor lysis syndrome, neurotoxicity and nausea\/vomiting. A review of patients\u2019 medications is imperative to eliminate medications that may contribute to treatment\u2010related toxicities. Studies are ongoing to help optimize patient selection, preparation, safety, and management of individuals receiving <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T cells. Long\u2010term follow\u2010up will help establish the place of <jats:styled-content style=\"fixed-case\">CAR<\/jats:styled-content> T cells in therapy.<\/jats:p>","DOI":"10.1002\/phar.1900","type":"journal-article","created":{"date-parts":[[2017,1,12]],"date-time":"2017-01-12T20:56:32Z","timestamp":1484254592000},"page":"334-345","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Chimeric Antigen Receptor T Cells in Hematologic Malignancies"],"prefix":"10.1002","volume":"37","author":[{"given":"Brandon R.","family":"Shank","sequence":"first","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Do","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Sevin","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheree E","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine, Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra B.","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","unstructured":"TurtleCJ HanafiL\u2010A BergerC et al.Rate of durable complete response in ALL NHL and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR\u2010T cells. ASCO Meeting Abstracts2016;15_suppl:102.","DOI":"10.1200\/JCO.2016.34.15_suppl.102"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","unstructured":"ParkJH RiviereI WangX PurdonT SadelainM BrentjensRJ.Impact of disease burden on long\u2010term outcome of 19\u201028z CAR modified T cells in adult patients with relapsed B\u2010ALL. ASCO Meeting Abstracts2016;15_suppl:7003.","DOI":"10.1200\/JCO.2016.34.15_suppl.7003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","unstructured":"MaudeSL TeacheyDT RheingoldSR et al.Sustained remissions with CD19\u2010specific chimeric antigen receptor (CAR)\u2010modified T cells in children with relapsed\/refractory ALL. ASCO Meeting Abstracts2016;15_suppl:3011.","DOI":"10.1200\/JCO.2016.34.15_suppl.3011"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","unstructured":"GardnerRA FinneyO SmithersH et al.Prolonged functional persistence of CD19 CAR T cell products of defined CD4:CD8 composition and transgene expression determines durability of MRD\u2010negative ALL remission. ASCO Meeting Abstracts2016;15_suppl:3048.","DOI":"10.1200\/JCO.2016.34.15_suppl.3048"},{"key":"e_1_2_7_6_1","unstructured":"FreyNV ShawPA HexnerEO et al.Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r\/r) acute lymphoblastic leukemia (ALL). ASCO Meeting Abstracts2016;15_suppl:7002."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"key":"e_1_2_7_9_1","unstructured":"PorterDL FreyNV MelenhorstJJ et al.Randomized phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (patients) with relapsed refractory (R\/R) CLL. ASCO Meeting Abstracts2016;15_suppl:3009."},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","unstructured":"GeyerMB ParkJH RiviereI et al.Updated results: phase I trial of autologous CD19\u2010targeted CAR T cells in patients with residual CLL following initial purine analog\u2010based therapy. ASCO Meeting Abstracts2016;15_suppl:7526.","DOI":"10.1200\/JCO.2016.34.15_suppl.7526"},{"key":"e_1_2_7_11_1","doi-asserted-by":"crossref","unstructured":"KochenderferJ SomervilleR LuT et al.Anti\u2010CD19 chimeric antigen receptor T cells preceded by low\u2010dose chemotherapy to induce remissions of advanced lymphoma. ASCO Meeting Abstracts2016;15_suppl:LBA3010.","DOI":"10.1200\/JCO.2016.34.15_suppl.LBA3010"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","unstructured":"SchusterSJ SvobodaJ NastaS et al.Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019). ASCO Meeting Abstracts2016;15_suppl:7564.","DOI":"10.1200\/JCO.2016.34.15_suppl.7564"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","unstructured":"SauterCS RiviereI BernalY et al.Phase I trial of 19\u201028z chimeric antigen receptor modified T cells (19\u201028z CAR\u2010T) post\u2010high dose therapy and autologous stem cell transplant (HDT\u2010ASCT) for relapsed and refractory (rel\/ref) aggressive B\u2010cell non\u2010Hodgkin lymphoma (B\u2010NHL). ASCO Annual Meeting Proceedings2015;15_suppl:8515.","DOI":"10.1200\/jco.2015.33.15_suppl.8515"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686725"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","unstructured":"NeelapuSS LockeFL BartlettNL et al.Ongoing complete remissions (CR) in the phase 1 of ZUMA\u20101: a phase 1\u20102 multicenter study evaluating the safety and efficacy of KTE\u2010C19 (anti\u2010CD19 CAR T cells) in subjects with refractory aggressive B\u2010cell non\u2010Hodgkin lymphoma (NHL). ASCO Meeting Abstracts2016;15_suppl:7559.","DOI":"10.1200\/JCO.2016.34.15_suppl.7559"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0485"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504542"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.167"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0421"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00144-2"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00693-2"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-043737"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.36"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.1982.1982"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.5"},{"key":"e_1_2_7_28_1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood.V91.1.347","article-title":"Impaired induction of the CD28\u2010responsive complex in granulocyte colony\u2010stimulating factor mobilized CD4 T cells","volume":"91","author":"Tanaka J","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.164"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.5929"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732"},{"key":"e_1_2_7_36_1","doi-asserted-by":"crossref","unstructured":"BotA RossiJM JiangY et al.Cy and Flu conditioning chemotherapy induces a key homeostatic cytokine profile in patients prior to CAR T cell therapy. 57th Annual Meeting & Exposition of American Society of Hematology;Orlando FL. Abstract 4426;2015.","DOI":"10.1182\/blood.V126.23.4426.4426"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0307298101"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621474"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.5449"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.4.1063"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0816-793"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2013.10.004"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068"},{"key":"e_1_2_7_51_1","unstructured":"Genentech Inc.Actemra (tocilizumab) package insert.San Francisco CA;2014."},{"key":"e_1_2_7_52_1","unstructured":"Redbook Online [online database].Greenwood Village CO:Truven Health Analytics. Accessed May 4 2016."},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-060512-150254"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000043"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e32834ec9c1"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.02.006"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620715588916"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2585-7"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_2_7_62_1","unstructured":"NCCN Guidelines. Antiemesis. Version 2.2016."},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2006.00505.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:29:01Z","timestamp":1761038941000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.1002\/phar.1900"],"URL":"https:\/\/doi.org\/10.1002\/phar.1900","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]},"assertion":[{"value":"2017-02-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}